Evaluating integrated MI and CBT for people with psychosis and substance misuse: Recruitment, retention and sample characteristics of the MIDAS trial

Evaluating integrated MI and CBT for people with psychosis and substance misuse: Recruitment, retention and sample characteristics of the MIDAS trial
复制标题

DOI:
10.1016/j.addbeh.2009.03.007
复制
发表时间:
2009-10-01
影响因子:
4.4
通讯作者:
Wykes, Til
Wykes, Til
中科院分区:
医学2区
文献类型:
--
作者:
Barrowclough, Christine;Haddock, Gillian;Wykes, Til

文献摘要

被引文献

相似文献

现有的随机对照试验评估精神病和药物滥用的心理社会干预的主要问题已经确定,特别是小样本量,高损耗率,和短期随访。英国的MIDAS试验样本量为327人,随访时间为2年,是迄今为止针对精神病和物质使用者的最大RCT,正在评估综合MI和CBT(“MiCBT”)客户治疗。虽然这项研究的结果尚未公布,但招募和保留的数据表明,MIDAS的流失率很低,大多数被分配接受治疗的人都接受了大量的治疗。样本特征与流行病学研究中报告的特征一致,并表明试图管理客户群体的心理健康服务所面临的挑战:药物使用通常是长期的,经常以中度或重度水平使用,改变的动力较低,并且在低水平的情况下出现功能和显着的精神病理学。我们的结论是,这是一个方法学上强大的研究,将有结果推广到精神卫生服务。(C)2009爱思唯尔有限公司保留所有权利。
Major problems with existing RCTs evaluating psychosocial interventions for psychosis and Substance misuse have been identified, in particular small sample sizes, high attrition rates, and short follow up periods. With a sample size of 327 and a follow up of 2 years, the MIDAS trial in the UK is to date the largest RCT for people with psychosis and Substance use and is evaluating an integrated MI and CBT ("MiCBT") client therapy. Whilst the outcomes of the study are not yet available, data oil recruitment and retention indicate that attrition rates in MIDAS are low and the majority of those allocated to treatment received a substantial number of therapy sessions. Sample characteristics are in line with those reported in epidemiological Studies and are indicative of the challenges facing mental health services attempting to manage the client group: Substance use is often longstanding, with frequent use at moderate or severe level and low motivation for change, and seen in the context of low levels of functioning and significant psychopathology. We conclude that this is a methodologically robust study that will have results generalisable to mental health services. (C) 2009 Elsevier Ltd. All rights reserved.